1
|
Long Y, Duan X, Fu Q, Liu M, Fu J, Song X, Mo R, You H, Qin L, Wang T, Li H, Ni G, Liu X, Yang W. Caerin 1.9-Titanium Plates Aid Implant Healing and Inhibit Bacterial Growth in New Zealand Rabbit Mandibles. Int Dent J 2024:S0020-6539(24)00127-8. [PMID: 38866671 DOI: 10.1016/j.identj.2024.04.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Revised: 03/31/2024] [Accepted: 04/22/2024] [Indexed: 06/14/2024] Open
Abstract
OBJECTIVES With rising rates of maxillofacial fracture, postoperative infection following rigid internal fixation is an important issue that requires immediate resolution. It is important to explore an alternative antibacterial method apart from conventional antibiotics. A controlled experiment was conducted to evaluate the effectiveness of a caerin 1.9 peptide-coated titanium plate in reducing mandibular infection in New Zealand (NZ) rabbits, aiming to minimise the risk of post-metallic implantation infection. METHODS Twenty-two NZ rabbits were randomly divided into 3 groups. The experiment group received caerin 1.9 peptide-coated titanium plates and mixed oral bacteria exposure. The control group received normal titanium plates with mixed oral bacteria exposure. The untreated group served as a control to prove that bacteria in the mouth can cause infection. Weight, temperature, hepatic function, and C-reactive protein levels were measured. Wound and bone conditions were evaluated. Further analysis included local infection, anatomic conditions, histology, and bacterial load. RESULTS No significant differences were found in temperature, weight, blood alanine aminotransferase, and C-reactive protein levels amongst the 3 groups. The experiment group showed the lowest amount of bacterial RNA in wounds. Additionally, the experiment group had higher peripheral lymphocyte counts compared to the control group and lower neutrophil counts on the third and seventh day postoperatively. Histologic analysis revealed lower levels of inflammatory cell infiltration, bleeding, and areas of necrosis in the experimental group compared with the controls. CONCLUSIONS A caerin 1.9-coated titanium plate is able to inhibit bacterial growth in a NZ rabbit mandibular mixed bacteria infection model and is worth further investigation.
Collapse
Affiliation(s)
- Yuqing Long
- School of Stomatology, Zunyi Medical University, Zunyi, Guizhou Province, China; Guiyang Dental Hospital, Guiyang, Guizhou Province, China
| | - Xubo Duan
- Medical School of Guizhou University, Guiyang, Guizhou Province, China
| | - Quanlan Fu
- Medical School of Guizhou University, Guiyang, Guizhou Province, China
| | - Mengqi Liu
- Medical School of Guizhou University, Guiyang, Guizhou Province, China
| | - Jiawei Fu
- Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China
| | - Xinyi Song
- Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China
| | - Rongmi Mo
- Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China
| | - Hang You
- School of Stomatology, Zunyi Medical University, Zunyi, Guizhou Province, China; Guiyang Dental Hospital, Guiyang, Guizhou Province, China
| | - Li Qin
- School of Stomatology, Zunyi Medical University, Zunyi, Guizhou Province, China; Guiyang Dental Hospital, Guiyang, Guizhou Province, China
| | - Tianfang Wang
- Centre for Bio-innovation, University of the Sunshine Coast, Maroochydore BC, Queensland 4558, Australia
| | - Hejie Li
- Centre for Bio-innovation, University of the Sunshine Coast, Maroochydore BC, Queensland 4558, Australia
| | - Guoying Ni
- Centre for Bio-innovation, University of the Sunshine Coast, Maroochydore BC, Queensland 4558, Australia; Cancer Research Institute, First People's Hospital of Foshan, Guangzhou, Guangdong Province, China
| | - Xiaosong Liu
- Cancer Research Institute, First People's Hospital of Foshan, Guangzhou, Guangdong Province, China
| | - Wei Yang
- School of Stomatology, Zunyi Medical University, Zunyi, Guizhou Province, China; Medical School of Guizhou University, Guiyang, Guizhou Province, China.
| |
Collapse
|
2
|
Wang Y, Zhong F, Xiao F, Li J, Liu X, Ni G, Wang T, Zhang W. Host-defence caerin 1.1 and 1.9 peptides suppress glioblastoma U87 and U118 cell proliferation through the modulation of mitochondrial respiration and induce the downregulation of CHI3L1. PLoS One 2024; 19:e0304149. [PMID: 38848430 PMCID: PMC11161062 DOI: 10.1371/journal.pone.0304149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2024] [Accepted: 05/08/2024] [Indexed: 06/09/2024] Open
Abstract
Glioblastoma, the most aggressive form of brain cancer, poses a significant global health challenge with a considerable mortality rate. With the predicted increase in glioblastoma incidence, there is an urgent need for more effective treatment strategies. In this study, we explore the potential of caerin 1.1 and 1.9, host defence peptides derived from an Australian tree frog, in inhibiting glioblastoma U87 and U118 cell growth. Our findings demonstrate the inhibitory impact of caerin 1.1 and 1.9 on cell growth through CCK8 assays. Additionally, these peptides effectively curtail the migration of glioblastoma cells in a cell scratch assay, exhibiting varying inhibitory effects among different cell lines. Notably, the peptides hinder the G0/S phase replication in both U87 and U118 cells, pointing to their impact on the cell cycle. Furthermore, caerin 1.1 and 1.9 show the ability to enter the cytoplasm of glioblastoma cells, influencing the morphology of mitochondria. Proteomics experiments reveal intriguing insights, with a decrease in CHI3L1 expression and an increase in PZP and JUNB expression after peptide treatment. These proteins play roles in cell energy metabolism and inflammatory response, suggesting a multifaceted impact on glioblastoma cells. In conclusion, our study underscores the substantial anticancer potential of caerin 1.1 and 1.9 against glioblastoma cells. These findings propose the peptides as promising candidates for further exploration in the realm of glioblastoma management, offering new avenues for developing effective treatment strategies.
Collapse
Affiliation(s)
- Yichen Wang
- The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, China
| | - Furong Zhong
- The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, China
- Zhongˈao Biomedical Technology (Guangdong) Co., Ltd, Zhongshan, Guangdong, China
| | - Fengyun Xiao
- The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, China
| | - Junjie Li
- The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, China
- Zhongˈao Biomedical Technology (Guangdong) Co., Ltd, Zhongshan, Guangdong, China
| | - Xiaosong Liu
- The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, China
- Zhongˈao Biomedical Technology (Guangdong) Co., Ltd, Zhongshan, Guangdong, China
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan, Guangdong, China
| | - Guoying Ni
- The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, China
- Zhongˈao Biomedical Technology (Guangdong) Co., Ltd, Zhongshan, Guangdong, China
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan, Guangdong, China
| | - Tianfang Wang
- Centre for Bioinnovation, University of the Sunshine Coast, Maroochydore BC, QLD, Australia
- School of Science, Technology and Engineering, University of the Sunshine Coast, Maroochydore BC, QLD, Australia
| | - Wei Zhang
- The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, China
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan, Guangdong, China
- Guangdong Provincial Engineering and Technology Research Center of Stem Cell Therapy for Pituitary Disease, Guangzhou, China
| |
Collapse
|
3
|
Yang X, Liu X, Li J, Zhang P, Li H, Chen G, Zhang W, Wang T, Frazer I, Ni G. Caerin 1.1/1.9 Enhances Antitumour Immunity by Activating the IFN-α Response Signalling Pathway of Tumour Macrophages. Cancers (Basel) 2022; 14:cancers14235785. [PMID: 36497272 PMCID: PMC9738106 DOI: 10.3390/cancers14235785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Revised: 11/09/2022] [Accepted: 11/21/2022] [Indexed: 11/27/2022] Open
Abstract
Macrophages are one of the essential components of the tumour microenvironment (TME) of many cancers and show complex heterogeneity and functions. More recent research has been focusing on the characterisation of tumour-associated macrophages (TAMs). Previously, our study demonstrated that caerin 1.1/1.9 peptides significantly improve the therapeutic efficacy of combined specific immunotherapy and immune checkpoint blockade in a murine transplantable tumour model (TC-1). In this study, the mice inoculated with TC-1 tumour were immunised differently. The TAMs were isolated using flow cytometry and characterised by cytokine ELISA. The survival rates of mice with different treatments containing caerin 1.1/19 were assessed comparatively, including those with/without macrophage depletion. The single-cell RNA sequencing (scRNA-seq) data of previous studies were integrated to further reveal the functions of TAMs with the treatments containing caerin 1.1/1.9. As a comparison, the TAMs of stage I and II cervical cancer patients were analysed using scRNA-seq analysis. We demonstrate that caerin induced tumour clearance is associated with infiltration of tumours by IL-12 secreting Ly6C+F4/80+ macrophages exhibiting enhanced IFN-α response signalling, renders animals resistant to further tumour challenge, which is lost after macrophage depletion. Our results indicate that caerin 1.1/1.9 treatment has great potential in improving current immunotherapy efficacy.
Collapse
Affiliation(s)
- Xiaodan Yang
- The First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou 510080, China
| | - Xiaosong Liu
- The First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou 510080, China
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan 528000, China
| | - Junjie Li
- The First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou 510080, China
| | - Pingping Zhang
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan 528000, China
| | - Hejie Li
- School of Science, Engineering and Technology, University of the Sunshine Coast, Maroochydore BC, QLD 4558, Australia
| | - Guoqiang Chen
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan 528000, China
| | - Wei Zhang
- The First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou 510080, China
| | - Tianfang Wang
- School of Science, Engineering and Technology, University of the Sunshine Coast, Maroochydore BC, QLD 4558, Australia
- Centre for Bioinnovation, University of the Sunshine Coast, Maroochydore BC, QLD 4558, Australia
| | - Ian Frazer
- Faculty of Medicine, University of Queensland Diamantina Institute, Translational Research Institute, the University of Queensland, Woolloongabba, QLD 4102, Australia
- Correspondence: (I.F.); (G.N.)
| | - Guoying Ni
- The First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou 510080, China
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan 528000, China
- Correspondence: (I.F.); (G.N.)
| |
Collapse
|
4
|
Anurans against SARS-CoV-2: A review of the potential antiviral action of anurans cutaneous peptides. Virus Res 2022; 315:198769. [PMID: 35430319 PMCID: PMC9008983 DOI: 10.1016/j.virusres.2022.198769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 04/05/2022] [Accepted: 04/06/2022] [Indexed: 01/17/2023]
Abstract
At the end of 2019, in China, clinical signs and symptoms of unknown etiology have been reported in several patients whose sample sequencing revealed pneumonia caused by the SARS-CoV-2 virus. COVID-19 is a disease triggered by this virus, and in 2020, the World Health Organization declared it a pandemic. Since then, efforts have been made to find effective therapeutic agents against this disease. Identifying novel natural antiviral drugs can be an alternative to treatment. For this reason, antimicrobial peptides secreted by anurans' skin have gained attention for showing a promissory antiviral effect. Hence, this review aimed to elucidate how and which peptides secreted by anurans' skin can be considered therapeutic agents to treat or prevent human viral infectious diseases. Through a literature review, we attempted to identify potential antiviral frogs' peptides to combat COVID-19. As a result, the Magainin-1 and -2 peptides, from the Magainin family, the Dermaseptin-S9, from the Dermaseptin family, and Caerin 1.6 and 1.10, from the Caerin family, are molecules that already showed antiviral effects against SARS-CoV-2 in silico. In addition to these peptides, this review suggests that future studies should use other families that already have antiviral action against other viruses, such as Brevinins, Maculatins, Esculentins, Temporins, and Urumins. To apply these peptides as therapeutic agents, experimental studies with peptides already tested in silico and new studies with other families not tested yet should be considered.
Collapse
|
5
|
Xiao L, Yang X, Li J, Zhang P, Tang S, Cao D, Chen S, Li H, Zhang W, Chen G, Ni G, Wang T, Liu X. Caerin 1 Peptides, the Potential Jack-of-All-Trades for the Multiple Antibiotic-Resistant Bacterial Infection Treatment and Cancer Immunotherapy. BIOMED RESEARCH INTERNATIONAL 2022; 2022:7841219. [PMID: 35445137 PMCID: PMC9015854 DOI: 10.1155/2022/7841219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Revised: 03/17/2022] [Accepted: 03/24/2022] [Indexed: 12/24/2022]
Abstract
Antibiotic resistance-related bacterial infections and cancers become huge challenges in human health in the 21st century. A number of naturally derived antimicrobial peptides possess multiple functions in host defense, including anti-infective and anticancer activities. One of which is known as the caerin 1 family peptides. The microbicidal properties of these peptides have been long discussed. The recent studies also established the usage of two members in this family, caerin 1.1 and caerin 1.9, in antimultiple antibiotic-resistant bacteria species. It is increasingly evident that caerin 1.1 and caerin 1.9 also contain additional activities in the suppression of tumor. In this review, we briefly outline the therapeutic potentials and possible mechanism of action of caerin 1.1 and 1.9 in the treatment of multiple antibiotic-resistant bacterial infection and cancer immunotherapy.
Collapse
Affiliation(s)
- Liyin Xiao
- The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China
- Zhongao Biomedical Co. Ltd, Guangzhou, Guangdong 510080, China
| | - Xiaodan Yang
- The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China
| | - Junjie Li
- The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China
| | - Pingping Zhang
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| | - Shuxian Tang
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| | - Dongmin Cao
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| | - Shu Chen
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| | - Hejie Li
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia
| | - Wei Zhang
- The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China
| | - Guoqiang Chen
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| | - Guoying Ni
- The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia
| | - Tianfang Wang
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia
| | - Xiaosong Liu
- The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China
- Zhongao Biomedical Co. Ltd, Guangzhou, Guangdong 510080, China
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| |
Collapse
|
6
|
Yang X, Li J, Chen S, Xiao L, Cao D, Wu X, Li H, Ni G, Wang T, Chen G, Liu X. Preclinical Pharmacokinetics, Biodistribution, and Acute Toxicity Evaluation of Caerin 1.9 Peptide in Sprague Dawley Rats. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE : ECAM 2022; 2022:9869293. [PMID: 35958922 PMCID: PMC9363195 DOI: 10.1155/2022/9869293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Revised: 06/03/2022] [Accepted: 06/16/2022] [Indexed: 11/17/2022]
Abstract
Caerin 1.9 is a natural peptide derived from the skin secretions of the Australian tree frog (Litoria) with broad-spectrum antimicrobial and anticancer bioactivity. It improves the efficacy of a therapeutic vaccine and immune checkpoint inhibitor therapy when injected intratumorally and inhibits TC-1 tumor growth when applied topically through intact skin in a TC-1 murine tumor model. This paper investigated the pharmaceutical kinetic profile, the tissue distribution, and the acute safety investigation of Caerin 1.9 peptide in Sprague Dawley (SD) rats. The results showed that subcutaneous injection of Caerin 1.9 at 100 mg/kg is safe and does not cause mortality or organ malfunction in the recipient rats. For the consecutive injection of F3 at 10 mg/kg, the peak concentration (C max) of F3 displayed at 1 hr after injection in male rats was 591 ng/mL, the average drug retention time was 0.807 hr, T 1/2 was 4.58 hr, and AUC0-last was 1890 h × ng/mL. In female rats, C max was 256 ng/mL, with an average drug retention time of 2.96 hr, T 1/2 of 1.33 hr, and AUC0-last of 740 h × ng/mL. The results showed that the concentration of Caerin 1.9 in the peripheral blood peaked at 1 hour. As injected concentration increased, T 1/2 extended, and C max, AUC0-last, and volume of distribution at a steady state all increased. After 14 days of repeated subcutaneous injection at 10.0 mg/kg, no accumulation of Caerin 1.9 in plasma was observed. The results of tissue distribution showed that the Caerin 1.9 is below the LC-MS/MS detection threshold at a minimum concentration of 40 ng/g. In conclusion, Caerin 1.9 is well tolerated in rats and could be used with current immunotherapies for better management of solid tumors and genital warts.
Collapse
Affiliation(s)
- Xiaodan Yang
- The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China
| | - Junjie Li
- The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China
| | - Shu Chen
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| | - Liyin Xiao
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| | - Dongmin Cao
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| | - Xiaolian Wu
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| | - Hejie Li
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia
| | - Guoying Ni
- The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia
| | - Tianfang Wang
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia
| | - Guoqiang Chen
- Department of Rheumatology, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| | - Xiaosong Liu
- The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| |
Collapse
|
7
|
Ni G, Liu X, Li H, Fogarty CE, Chen S, Zhang P, Liu Y, Wu X, Wei MQ, Chen G, Zhang P, Wang T. Topical Application of Temperature-Sensitive Gel Containing Caerin 1.1 and 1.9 Peptides on TC-1 Tumour-Bearing Mice Induced High-Level Immune Response in the Tumour Microenvironment. Front Oncol 2021; 11:754770. [PMID: 34858827 PMCID: PMC8632150 DOI: 10.3389/fonc.2021.754770] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2021] [Accepted: 10/11/2021] [Indexed: 01/22/2023] Open
Abstract
The development of topical cream drugs that increase the immune activation of tumour-infiltrating lymphocytes against tumour and chronic viral infection-associated lesions is of great immunotherapeutic significance. This study demonstrates that the topical application of a temperature-sensitive gel containing caerin 1.1 and 1.9 peptides reduces nearly 50% of the tumour weight of HPV16 E6/E7-transformed TC-1 tumour-bearing mice via improving the tumour microenvironment. Confocal microscopy confirms the time-dependent penetration of caerin 1.9 through the epidermal layer of the ear skin structure of mice. Single-cell transcriptomic analysis shows that the caerin 1.1/1.9 gel expands the populations with high immune activation level and largely stimulates the pro-inflammatory activity of NK and dendritic cells. Closely associated with INFα response, Cebpb seems to play a key role in altering the function of all Arg1hi macrophages in the caerin group. In addition, the caerin gel treatment recruits almost two-fold more activated CD8+ T cells to the TME, relative to the untreated tumour, which shows a synergistic effect derived from the regulation of S1pr1, Ccr7, Ms4a4b and Gimap family expression. The TMT10plex-labelling proteomic quantification further demonstrates the activation of interferon-alpha/beta secretion and response to cytokine stimulus by the caerin gel, while the protein contents of several key regulators were elevated by more than 30%, such as Cd5l, Gzma, Ifit1, Irf9 and Stat1. Computational integration of the proteome with the single-cell transcriptome consistently suggested greater activation of NK and T cells with the topical application of caerin peptide gel.
Collapse
Affiliation(s)
- Guoying Ni
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, China.,Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD, Australia.,Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.,The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University , Guangzhou, China
| | - Xiaosong Liu
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, China.,Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD, Australia
| | - Hejie Li
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD, Australia.,School of Science, Technology and Engineering, University of the Sunshine Coast, Maroochydore DC, QLD, Australia
| | - Conor E Fogarty
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD, Australia.,School of Science, Technology and Engineering, University of the Sunshine Coast, Maroochydore DC, QLD, Australia
| | - Shu Chen
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, China
| | - Pingping Zhang
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, China
| | - Ying Liu
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, China
| | - Xiaolian Wu
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, China
| | - Ming Q Wei
- Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia
| | - Guoqiang Chen
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, China
| | - Ping Zhang
- Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia
| | - Tianfang Wang
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD, Australia.,School of Science, Technology and Engineering, University of the Sunshine Coast, Maroochydore DC, QLD, Australia
| |
Collapse
|
8
|
Chen S, Zhang P, Xiao L, Liu Y, Wu K, Ni G, Li H, Wang T, Wu X, Chen G, Liu X. Caerin 1.1 and 1.9 Peptides from Australian Tree Frog Inhibit Antibiotic-Resistant Bacteria Growth in a Murine Skin Infection Model. Microbiol Spectr 2021; 9:e0005121. [PMID: 34259550 PMCID: PMC8552723 DOI: 10.1128/spectrum.00051-21] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Accepted: 06/18/2021] [Indexed: 01/04/2023] Open
Abstract
The host defense peptide caerin 1.9 was originally isolated from skin secretions of an Australian tree frog and inhibits the growth of a wide range of bacteria in vitro. In this study, we demonstrated that caerin 1.9 shows high bioactivity against several bacteria strains, such as Staphylococcus aureus, Acinetobacter baumannii, methicillin-resistant Staphylococcus aureus (MRSA), and Streptococcus haemolyticus in vitro. Importantly, unlike the antibiotic Tazocin, caerin 1.9 does not induce bacterial resistance after 30 rounds of in vitro culture. Moreover, caerin 1.1, another peptide of the caerin family, has an additive antibacterial effect when used together with caerin 1.9. Furthermore, caerin 1.1 and 1.9 prepared in the form of a temperature-sensitive gel inhibit MRSA growth in a skin bacterial infection model of two murine strains. These results indicate that caerin 1.1 and 1.9 peptides could be considered an alternative for conventional antibiotics. IMPORTANCE Antibiotic-resistant bacteria cause severe problems in the clinic. We show in our paper that two short peptides isolated from an Australian frog and prepared in the form of a gel are able to inhibit the growth of antibiotic-resistant bacteria in mice, and, unlike antibiotics, these peptides do not lead to the development of peptide-resistant bacteria strains.
Collapse
Affiliation(s)
- Shu Chen
- Cancer Research Institute, Foshan First People’s Hospital, Foshan, Guangdong, China
| | - Pingping Zhang
- Cancer Research Institute, Foshan First People’s Hospital, Foshan, Guangdong, China
| | - Liyin Xiao
- Cancer Research Institute, Foshan First People’s Hospital, Foshan, Guangdong, China
| | - Ying Liu
- Cancer Research Institute, Foshan First People’s Hospital, Foshan, Guangdong, China
| | - Kuihai Wu
- Clinical Microbiological Laboratory, Foshan First People’s Hospital, Foshan, Guangdong, China
| | - Guoying Ni
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore, QLD, Australia
- Department of Rheumatology, Foshan Frist People’s Hospital, Foshan, Guangdong, China
| | - Hejie Li
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore, QLD, Australia
| | - Tianfang Wang
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore, QLD, Australia
| | - Xiaolian Wu
- Cancer Research Institute, Foshan First People’s Hospital, Foshan, Guangdong, China
| | - Guoqiang Chen
- Department of Rheumatology, Foshan Frist People’s Hospital, Foshan, Guangdong, China
| | - Xiaosong Liu
- Cancer Research Institute, Foshan First People’s Hospital, Foshan, Guangdong, China
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore, QLD, Australia
| |
Collapse
|
9
|
Ni G, Yang X, Li J, Wu X, Liu Y, Li H, Chen S, Fogarty CE, Frazer IH, Chen G, Liu X, Wang T. Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TC-1 tumor-bearing mice with PD-1 blockade by modulating macrophage heterogeneity and the activation of CD8 + T cells in the tumor microenvironment. Clin Transl Immunology 2021; 10:e1335. [PMID: 34429969 PMCID: PMC8369845 DOI: 10.1002/cti2.1335] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 06/25/2021] [Accepted: 08/05/2021] [Indexed: 12/11/2022] Open
Abstract
OBJECTIVES Developing a vaccine formula that alters the tumor-infiltrating lymphocytes to be more immune active against a tumor is key to the improvement of clinical responses to immunotherapy. Here, we demonstrate that, in conjunction with E7 antigen-specific immunotherapy, and IL-10 and PD-1 blockade, intratumoral administration of caerin 1.1/1.9 peptides improves TC-1 tumor microenvironment (TME) to be more immune active than injection of a control peptide. METHODS We compared the survival time of vaccinated TC-1 tumor-bearing mice with PD-1 and IL-10 blockade, in combination with a further injection of caerin 1.1/1.9 or control peptides. The tumor-infiltrating haematopoietic cells were examined by flow cytometry. Single-cell transcriptomics and proteomics were used to quantify changes in cellular activity across different cell types within the TME. RESULTS The injection of caerin 1.1/1.9 increased the efficacy of vaccinated TC-1 tumor-bearing mice with anti-PD-1 treatment and largely expanded the populations of macrophages and NK cells with higher immune activation level, while reducing immunosuppressive macrophages. More activated CD8+ T cells were induced with higher populations of memory and effector-memory CD8+ T subsets. Computational integration of the proteome with the single-cell transcriptome supported activation of Stat1-modulated apoptosis and significant reduction in immune-suppressive B-cell function following caerin 1.1 and 1.9 treatment. CONCLUSIONS Caerin 1.1/1.9-containing treatment results in improved antitumor responses. Harnessing the novel candidate genes preferentially enriched in the immune active cell populations may allow further exploration of distinct macrophages, T cells and their functions in TC-1 tumors.
Collapse
Affiliation(s)
- Guoying Ni
- Cancer Research InstituteFirst People’s Hospital of FoshanFoshanGuangdongChina
- Genecology Research CentreUniversity of the Sunshine CoastMaroochydore DCQLDAustralia
- The First Affiliated Hospital/Clinical Medical SchoolGuangdong Pharmaceutical UniversityGuangzhouChina
| | - Xiaodan Yang
- The First Affiliated Hospital/Clinical Medical SchoolGuangdong Pharmaceutical UniversityGuangzhouChina
| | - Junjie Li
- The First Affiliated Hospital/Clinical Medical SchoolGuangdong Pharmaceutical UniversityGuangzhouChina
| | - Xiaolian Wu
- Cancer Research InstituteFirst People’s Hospital of FoshanFoshanGuangdongChina
| | - Ying Liu
- Cancer Research InstituteFirst People’s Hospital of FoshanFoshanGuangdongChina
| | - Hejie Li
- Genecology Research CentreUniversity of the Sunshine CoastMaroochydore DCQLDAustralia
| | - Shu Chen
- Cancer Research InstituteFirst People’s Hospital of FoshanFoshanGuangdongChina
| | - Conor E Fogarty
- Genecology Research CentreUniversity of the Sunshine CoastMaroochydore DCQLDAustralia
| | - Ian H Frazer
- Faculty of MedicineUniversity of Queensland Diamantina InstituteTranslational Research InstituteThe University of QueenslandWoolloongabbaQLDAustralia
| | - Guoqiang Chen
- Cancer Research InstituteFirst People’s Hospital of FoshanFoshanGuangdongChina
| | - Xiaosong Liu
- Cancer Research InstituteFirst People’s Hospital of FoshanFoshanGuangdongChina
- Genecology Research CentreUniversity of the Sunshine CoastMaroochydore DCQLDAustralia
- The First Affiliated Hospital/Clinical Medical SchoolGuangdong Pharmaceutical UniversityGuangzhouChina
| | - Tianfang Wang
- Genecology Research CentreUniversity of the Sunshine CoastMaroochydore DCQLDAustralia
| |
Collapse
|
10
|
Lin R, Ma B, Liu N, Zhang L, He T, Liu X, Chen T, Liu W, Liang Y, Wang T, Ni G, Liu X, Yang N, Zhang J, Yuan J. Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice. Ann Nucl Med 2021; 35:811-822. [PMID: 33948902 PMCID: PMC8197720 DOI: 10.1007/s12149-021-01618-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Accepted: 04/20/2021] [Indexed: 12/19/2022]
Abstract
Objective The combination of two or more drugs with different mechanisms is a promising strategy for cancer treatment, and radioimmunotherapy (RIT) is a trending antitumor strategy. Radiotherapy (RT) can promote and activate antitumor immune effects, and immunotherapy can strengthen the effects of selective internal radiotherapy (SIRT); the RIT combination is synergistic and can overcome the adverse side effects of monotherapy. In this study, we developed a radioimmunoconjugate (RIC)—the iodine-131 (131I)-labeled caerin 1.1 peptide—to treat human anaplastic thyroid cancer (ATC). Methods Antitumor activity of caerin 1.1 peptide was determined by MTT assay, plate colony formation and cell wound scratch assays, and the mechanism of the inhibition of carein 1.1 peptide on the growth of CAL-62 cells was identified by cell cycle and western blot. Then, we investigated the efficacy of the caerin 1.1 peptide as a single drug and the 131I-labeled caerin 1.1 peptide for ATC. H&E and TUNEL staining was performed to detect dead cells in the tumor tissue sections. Results We found that caerin 1.1 arrested cells in the S phase to induce apoptosis and inhibited tumor growth to inhibit phosphorylation of Akt. In vivo, the iodine-131 (131I)-labeled caerin 1.1 peptide achieved better antitumor efficacy than radiotherapy alone and showed a good biosafety profile. Conclusions Our study demonstrates for the first time that the iodine-131 (131I)-labeled caerin 1.1 peptide can inhibit CAL-62 tumor growth and migration. The iodine-131 (131I)-labeled caerin 1.1 peptide, which represents a radioimmunotherapy strategy based on the combination of SIRT with a peptide–drug conjugate, could provide a treatment means for the radical cure of ATC.
Collapse
Affiliation(s)
- Ruoting Lin
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China
| | - Bowei Ma
- Department of TCM Resident Training, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, 510405, Guangdong, China
| | - Na Liu
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China
| | - Lu Zhang
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China
| | - Tiantian He
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China
| | - Xiongying Liu
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China
| | - Tongsheng Chen
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China
| | - Wenjuan Liu
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China
| | - Yongnan Liang
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China
| | - Tianfang Wang
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China
- Genecology Research Centre, University of Sunshine Coast, Maroochydore DC, QLD, 4558, Australia
| | - Guoying Ni
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China
- Genecology Research Centre, University of Sunshine Coast, Maroochydore DC, QLD, 4558, Australia
| | - Xiaosong Liu
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China
- The First People's Hospital of Foshan, Foshan, 528000, Guangdong, China
- Genecology Research Centre, University of Sunshine Coast, Maroochydore DC, QLD, 4558, Australia
| | - Ning Yang
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China
| | - Jinhe Zhang
- Department of Nuclear Medicine, General Hospital of the Southern Theatre Command, People's Liberation Army of China, Guangzhou, 510010, Guangdong, China
| | - Jianwei Yuan
- Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, Guangdong, China.
| |
Collapse
|
11
|
Wang T, Ni G, Furushima T, Diao H, Zhang P, Chen S, Fogarty CE, Jiang Z, Liu X, Li H. Mg alloy surface immobilised with caerin peptides acquires enhanced antibacterial ability and putatively improved corrosion resistance. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2021; 121:111819. [PMID: 33579462 DOI: 10.1016/j.msec.2020.111819] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Revised: 12/14/2020] [Accepted: 12/16/2020] [Indexed: 01/04/2023]
Abstract
Magnesium (Mg) has mechanical properties similar to human bones and Mg alloy is considered ideal medical implant material. However, the high velocity of degradation inside the human inner environment severely hampers the usage of Mg alloys. In this study, caerin peptide 1.9 (F3) and a modified sequence of caerin 1.1 (F1) with anti-bacterial activity, were covalently immobilised on the surface of Mg alloys by plasma chemical click reaction. The in vitro antibacterial activity and corrosion resistance of these caerin peptide-immobilised Mg alloys were investigated in Dulbecco's Modified Eagle Medium (DMEM) solution. Un-immobilised Mg alloy sample, blank drug-sensitive tablet (BASD) and a commonly used antibiotics Tazocin were used for comparison. Results showed that peptide immobilised Mg samples showed observable improved corrosion resistance and prolonged antibacterial effect compared to non-immobilised Mg alloy and free caerin peptides. These results indicate that coating Mg alloy with caerin peptides obviously increases the alloy's antibacterial ability and putatively improves the corrosion resistance in vitro. The mechanism underlying the prolonged antibacterial effect for annealed Mg alloys immobilised with the peptides (especially F3) remains unclear, which worth further experimental and theoretical investigation.
Collapse
Affiliation(s)
- Tianfang Wang
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia
| | - Guoying Ni
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia; The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou 510080, China
| | - Tsuyoshi Furushima
- Institute of Industrial Science, Department of Mechanical and Biofunctional Systems, The University of Tokyo, 4-6-1, Komaba, Meguro, Tokyo 153-8505, Japan
| | - Hui Diao
- Centre for Microscopy and Microanalysis, University of Queensland, St. Lucia, QLD 4072, Australia
| | - Pingping Zhang
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| | - Shu Chen
- Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China
| | - Conor E Fogarty
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia
| | - Zhengyi Jiang
- School of Mechanical, Materials, Mechatronic and Biomedical Engineering, Faculty of Engineering and Information Sciences, University of Wollongong, Northfields Ave, Wollongong, NSW 2522, Australia
| | - Xiaosong Liu
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia; Cancer Research Institute, First People's Hospital of Foshan, Foshan, Guangdong 528000, China.
| | - Hejie Li
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD 4558, Australia; Institute of Industrial Science, Department of Mechanical and Biofunctional Systems, The University of Tokyo, 4-6-1, Komaba, Meguro, Tokyo 153-8505, Japan.
| |
Collapse
|
12
|
Ni G, Chen S, Chen M, Wu J, Yang B, Yuan J, Walton SF, Li H, Wei MQ, Wang Y, Chen G, Liu X, Wang T. Host-Defense Peptides Caerin 1.1 and 1.9 Stimulate TNF-Alpha-Dependent Apoptotic Signals in Human Cervical Cancer HeLa Cells. Front Cell Dev Biol 2020; 8:676. [PMID: 32850805 PMCID: PMC7412766 DOI: 10.3389/fcell.2020.00676] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2020] [Accepted: 07/03/2020] [Indexed: 01/07/2023] Open
Abstract
Host defense caerin 1.1 and 1.9 peptides, isolated from the glandular secretion of Australian tree frogs, the genus Litoria, have been previously shown to have multiple biological activities, including the inhibition of human papillomavirus (HPV) 16 early protein E7 transformed murine as well as human cancerous cell proliferation both in vitro and in vivo. However, the mechanism underlying their anti-proliferative activities against HPV18+ cervical cancer HeLa cells remains unknown. This study comparatively investigated the anti-proliferation on HeLa cells by caerin 1.1, 1.9, and their mixture, followed by confocal microscopy examination to assess the cellular intake of the peptides. Tandem mass tag labeling proteomics was employed to reveal the proteins that were significantly regulated by the peptide treatment in cells and cell growth environment, to elucidate the signaling pathways that were modulated. Western blot was performed to confirm the modulation of the pathways. Both caerin 1.1 and 1.9 highly inhibited HeLa cell proliferation with a significant additive effect compared to untreated and control peptide. They entered the cells with different magnitudes. Intensive protein-protein interaction was detected among significantly upregulated proteins. Translation, folding and localization of proteins and RNA processing, apoptosis process was significantly enriched post the treatments. The apoptotic signaling was suggested as a result of tumor necrosis factor-α (TNF-α) pathway activation, indicated by the dose-dependent elevated levels of caspase 3 and caspase 9. The epidermal growth factor receptor and androgen receptor pathways appeared inhibited by the peptides. Moreover, the activation of T-cell receptor derived from the quantitation results further implies the likelihood of recruiting more T cells to the cell growth environment post the treatment and more sensitive to T cell mediated killing of HeLa cells. Our results indicate that caerin 1.1 and 1.9 mediate apoptotic signals of HeLa cells and may subsequently enhances adaptive T cell immune responses.
Collapse
Affiliation(s)
- Guoying Ni
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan, China
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore, QLD, Australia
- The First Affiliated Hospital, School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, China
| | - Shu Chen
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan, China
| | - Mo Chen
- Menzies Health Institute Queensland and School of Medical Science, Griffith University, Southport, QLD, Australia
| | - Jialing Wu
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan, China
| | - Binbin Yang
- Menzies Health Institute Queensland and School of Medical Science, Griffith University, Southport, QLD, Australia
- Department of Laboratory Medicine, Institute of Nanomedicine Technology, Weifang Medical University, Weifang, China
| | - Jianwei Yuan
- The First Affiliated Hospital, School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, China
| | - Shelley F. Walton
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore, QLD, Australia
| | - Hejie Li
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore, QLD, Australia
- Department of Mechanical and Biofunctional System, Institute of Industrial Science, The University of Tokyo, Tokyo, Japan
| | - Ming Q. Wei
- Menzies Health Institute Queensland and School of Medical Science, Griffith University, Southport, QLD, Australia
| | - Yuejian Wang
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan, China
| | - Guoqiang Chen
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan, China
| | - Xiaosong Liu
- Cancer Research Institute, First People’s Hospital of Foshan, Foshan, China
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore, QLD, Australia
- The First Affiliated Hospital, School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, China
| | - Tianfang Wang
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore, QLD, Australia
| |
Collapse
|
13
|
Ni G, Zhang L, Yang X, Li H, Ma B, Walton S, Wu X, Yuan J, Wang T, Liu X. Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task. Hum Vaccin Immunother 2020; 16:2328-2332. [PMID: 32159421 DOI: 10.1080/21645515.2020.1717185] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Interleukin 10 (IL-10) belongs to IL-10 family cytokines that are critical for maintaining the integrity of epithelial tissues, protecting pathogenic infection, and preventing excessive immune responses to damage self. Temporal IL-10 signaling blockade enhances vaccine-induced tumor regression by CD8 + T cells. IL-10, especially pegylated IL-10, mediates tumor regression by expanding tumor-infiltrating CD8 + T cells. Moreover, targeting IL-10 enhances immune checkpoint inhibitor mediated tumor regression. In the current paper, we will review recent advances in this area and discuss the complexity of IL-10 manipulation for cancer therapy.
Collapse
Affiliation(s)
- Guoying Ni
- Department of Nuclear Medicine, The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University , Guangzhou, China.,Genecology Research Centre, University of the Sunshine Coast , Maroochydore, Australia.,School of Medical Science, Griffith Health Institute, Griffith University , Gold Coast, Australia
| | - Lu Zhang
- Department of Nuclear Medicine, The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University , Guangzhou, China
| | - Xiaodan Yang
- Department of Nuclear Medicine, The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University , Guangzhou, China
| | - Hejie Li
- Genecology Research Centre, University of the Sunshine Coast , Maroochydore, Australia.,Institute of Industrial Science, Department of Mechanical and Bio-functional System, The University of Tokyo , Tokyo, Japan
| | - Bowei Ma
- Department of Nuclear Medicine, The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University , Guangzhou, China
| | - Shelley Walton
- Genecology Research Centre, University of the Sunshine Coast , Maroochydore, Australia
| | - Xiaolian Wu
- Cancer Research Institute, First People's Hospital of Foshan , Foshan, Guangdong, China
| | - Jianwei Yuan
- Department of Nuclear Medicine, The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University , Guangzhou, China
| | - Tianfang Wang
- Genecology Research Centre, University of the Sunshine Coast , Maroochydore, Australia
| | - Xiaosong Liu
- Department of Nuclear Medicine, The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University , Guangzhou, China.,Genecology Research Centre, University of the Sunshine Coast , Maroochydore, Australia.,Cancer Research Institute, First People's Hospital of Foshan , Foshan, Guangdong, China.,School of Health and Sport Sciences, University of the Sunshine Coast , Maroochydore, Australia
| |
Collapse
|
14
|
Ma B, Yuan J, Chen S, Huang K, Wang Q, Ma J, Lin R, Zhang L, Zhou Y, Wang T, Walton SF, Pan X, Chen G, Wang Y, Ni G, Liu X. Topical application of temperature-sensitive caerin 1.1 and 1.9 gel inhibits TC-1 tumor growth in mice. Am J Transl Res 2020; 12:191-202. [PMID: 32051748 PMCID: PMC7013226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Accepted: 01/02/2020] [Indexed: 06/10/2023]
Abstract
Genital warts, which are one of the most common sexually transmitted diseases (STDs), result from persistent infection with human papillomavirus (HPV), especially subtypes 6 or 11. Topical application of 5% imiquimod cream is currently recommended as a first-line treatment choice for genital warts, but the clearance and patient compliance rates remain less than sufficient. In the current study, we developed a temperature-sensitive gel that contains the host-defense peptides caerin 1.1 and 1.9, which were originally isolated from Australian tree frogs of the genus Litoria. Growth of HPV16 E6/E7-transformed TC-1 cells was inhibited in vitro and in vivo following injection of the tumor with the caerin gel in a TC-1 tumor mouse model. Furthermore, when the caerin gel was topically applied, the inhibitory effect remained, and T, NK cells were attracted to the tumor site. In addition, the gel maintained a similar level of bioactivity after incubation at room temperature for 30 days. Our results suggest that this caerin gel, following further optimization, may provide an alternative method for the management of genital warts.
Collapse
Affiliation(s)
- Bowei Ma
- The First Affiliated Hospital/Clinical Medical School, Department of Nuclear Medicine, Guangdong Pharmaceutical UniversityGuangzhou 510080, Guangdong, China
| | - Jianwei Yuan
- The First Affiliated Hospital/Clinical Medical School, Department of Nuclear Medicine, Guangdong Pharmaceutical UniversityGuangzhou 510080, Guangdong, China
| | - Shu Chen
- Cancer Research Institute, Foshan First People’s HospitalFoshan 528000, Guangdong, China
| | - Kunsong Huang
- The First Affiliated Hospital/Clinical Medical School, Department of Nuclear Medicine, Guangdong Pharmaceutical UniversityGuangzhou 510080, Guangdong, China
| | - Qianbo Wang
- The First Affiliated Hospital/Clinical Medical School, Department of Nuclear Medicine, Guangdong Pharmaceutical UniversityGuangzhou 510080, Guangdong, China
| | - Jianchun Ma
- The First Affiliated Hospital/Clinical Medical School, Department of Nuclear Medicine, Guangdong Pharmaceutical UniversityGuangzhou 510080, Guangdong, China
| | - Ruoting Lin
- The First Affiliated Hospital/Clinical Medical School, Department of Nuclear Medicine, Guangdong Pharmaceutical UniversityGuangzhou 510080, Guangdong, China
| | - Lu Zhang
- The First Affiliated Hospital/Clinical Medical School, Department of Nuclear Medicine, Guangdong Pharmaceutical UniversityGuangzhou 510080, Guangdong, China
| | - Yingying Zhou
- The First Affiliated Hospital/Clinical Medical School, Department of Nuclear Medicine, Guangdong Pharmaceutical UniversityGuangzhou 510080, Guangdong, China
| | - Tianfang Wang
- Genecology Research Centre, University of Sunshine CoastMaroochydore DC, QLD 4558, Australia
| | - Shelley F Walton
- Inflammation and Healing Research Cluster, School of Health and Sport Sciences, University of Sunshine CoastMaroochydore DC, QLD 4558, Australia
| | - Xuan Pan
- The First Affiliated Hospital/Clinical Medical School, Department of Nuclear Medicine, Guangdong Pharmaceutical UniversityGuangzhou 510080, Guangdong, China
| | - Guoqiang Chen
- Cancer Research Institute, Foshan First People’s HospitalFoshan 528000, Guangdong, China
| | - Yuejian Wang
- Cancer Research Institute, Foshan First People’s HospitalFoshan 528000, Guangdong, China
| | - Guoying Ni
- The First Affiliated Hospital/Clinical Medical School, Department of Nuclear Medicine, Guangdong Pharmaceutical UniversityGuangzhou 510080, Guangdong, China
- Inflammation and Healing Research Cluster, School of Health and Sport Sciences, University of Sunshine CoastMaroochydore DC, QLD 4558, Australia
- Genecology Research Centre, University of Sunshine CoastMaroochydore DC, QLD 4558, Australia
| | - Xiaosong Liu
- The First Affiliated Hospital/Clinical Medical School, Department of Nuclear Medicine, Guangdong Pharmaceutical UniversityGuangzhou 510080, Guangdong, China
- Cancer Research Institute, Foshan First People’s HospitalFoshan 528000, Guangdong, China
- Inflammation and Healing Research Cluster, School of Health and Sport Sciences, University of Sunshine CoastMaroochydore DC, QLD 4558, Australia
| |
Collapse
|